Bernstein Harold 4

4 · Maze Therapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Maze (MAZE) President Harold Bernstein Exercises Options, Sells Shares

What Happened

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, exercised options to acquire 15,000 shares at $10.42 each (cost $156,300) on Feb 2, 2026.
On the same day he sold a total of 15,000 shares in multiple open-market transactions for aggregate proceeds of approximately $690,333 (sales were executed at several prices; weighted averages reported).
The filing also reports a 15,000-share derivative disposition at $0.00 on the same date (see Key Details and Footnotes).

Key Details

Transaction date: February 2, 2026; Form 4 filed Feb 4, 2026 (timely).
Exercise/acquisition: 15,000 shares at $10.42 each — $156,300 total.
Open-market sales: four lots totaling 15,000 shares; reported proceeds ≈ $690,333. Reported weighted-average prices correspond to ranges: $44.15–$44.29, $45.20–$46.19, $46.20–$47.17 (see footnotes F2–F4).
Derivative disposition: 15,000 shares reported at $0.00 (listed as a derivative transaction).
Shares owned after the transactions: not specified in the provided filing details.
Notable footnotes: F1 — sales effected under a Rule 10b5-1 trading plan adopted Sept 29, 2025; F5 — vesting schedule for the option award (1/4 on Oct 3, 2023 then monthly 1/48th thereafter). F2–F4 explain weighted-average pricing ranges and offer to provide detailed per-price sale breakdowns on request.

Context

This filing shows both an option exercise (acquisition) and immediate sales; exercises followed by same-day sales are often used to cover exercise costs or realize gains. The sales were executed under a pre-existing 10b5-1 plan (per F1), indicating pre-scheduled transactions rather than ad hoc trading.
The derivative line reported at $0.00 and the vesting footnote relate to the option/award mechanics; the filing does not itself explain whether shares were surrendered for taxes or other internal settlement mechanics.

Form 4

Period: 2026-02-02

President, R&D & CMO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-02$10.42/sh+15,000$156,300→ 15,000 total
Sale
Common Stock
[F1][F2]
2026-02-02$44.20/sh−600$26,523→ 14,400 total
Sale
Common Stock
[F1][F3]
2026-02-02$45.89/sh−8,364$383,816→ 6,036 total
Sale
Common Stock
[F1][F4]
2026-02-02$46.37/sh−5,936$275,271→ 100 total
Sale
Common Stock
[F1]
2026-02-02$47.23/sh−100$4,723→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]
2026-02-02−15,000→ 297,407 total
Exercise: $10.42Exp: 2032-10-26→ Common Stock (15,000 underlying)

Footnotes (5)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.29 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.20 to $46.19 per share, inclusive.
[F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.20 to $47.17 per share, inclusive.
[F5]The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-02-04

1 file